Ustralia. Med J Aust. 1989;150:613?19. 11. Mitchell A. Case control study of neural tube defects and periconceptional vitamin use. Paediatr Perinat Epidemiol. 1989;three:216. 12. Vergel RG, Sanchez LR, Heredero BL, Rodriguez PL, Martinez AJ. Main prevention of neural tube defects with folic acid supplementation: Cuban expertise. Prenat Diagn. 1990;ten:149?52. 13. Czeizel AE, Dudas I. Prevention from the initially occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832?835. 14. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA. 1993;269:1257?261. 15. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, plus the occurrence of neural tube defects. Epidemiology. 1995;six:219?26. 16. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in china. China-US. Collaborative project for neural tube defect prevention. N Engl J Med. 1999;341:1485?490. 17. De-Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP. Effects and security of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010; ten: CD007950. 18. Mathews TJ, Honein MA, Erickson JD. Spina bifida and anencephaly prevalence ?United states of america, 1991?001. MMWR Recomm Rep. 2002;51:9?1. 19. Ray JG, Singh G, Burrows RF. Evidence for suboptimal use of periconceptional folic acid supplements globally. BJOG. 2004;111:399?08. 20. Tinker SC, Cogswell ME, Devine O, Berry RJ. Folic acid intake amongst US women aged 15?four years, National Overall health and Nutrition Examination Survey, 2003?006. Am J Prev Med. 2010;38:534?42. 21. Spina bifida and anencephaly before and right after folic acid mandate ?United states, 1995?996 and 1999?000.(S)-3-Bromo-2-methylpropan-1-ol uses MMWR Morb Mortal Wkly Rep.Cesium carbonate,99.9% custom synthesis 2004;53:362?65.PMID:23415682 22. US Food and Drug Administration. Summary minutes advisory committee for reproductive overall health drugs meeting, December 15, 2003. Accessible from: http://fda.gov/ohrms/dockets/ac/03/minutes/4002M1_Final. pdf. Accessed January 24, 2013. 23. Lassi ZS, Bhutta ZA. Clinical utility of folate-containing oral contraceptives. Int J Womens Health. 2012;four:185?90. 24. Lamers Y, Prinz-Langenohl R, Bramswig S, Pietrzik K. Red blood cell folate concentrations enhance a lot more right after supplementation with [6s]-5methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr. 2006;84:156?61. 25. Lamers Y, Prinz-Langenohl R, Moser R, Pietrzik K. Supplementation with [6s]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in wholesome women. Am J Clin Nutr. 2004;79:473?78.events have been deemed to be treatment-related plus the tolerability profiles of EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid for the duration of the invasion phase were constant with those of other oral contraceptives.42?4 All round, these final results confirm that addition of folate to an oral contraceptive does not give rise to additional security issues. In summary, treatment with EE-drospirenone-levomefolate calcium for 24 weeks resulted in similar prices of raise and, following cessation of remedy, in comparable prices of reduce in plasma and RBC folate levels compared with therapy using EE-drospirenone + folic acid. The impact on plasma homocysteine levels was also comparable between the two treatment options. Within a substantial proportion of girls, folate levels remained above those at baseli.